{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:18Z","timestamp":1793411958109,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41375-019-0487-8","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T13:03:06Z","timestamp":1559134986000},"page":"1996-2005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study"],"prefix":"10.1038","volume":"33","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Masciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Di Veroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Delaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-2906","authenticated-orcid":false,"given":"Andrea","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9504","authenticated-orcid":false,"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Carola","family":"Casetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemency","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Maria","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Palova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Erez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Perez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-8597","authenticated-orcid":false,"given":"Valle","family":"Recasens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Larran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"487_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"487_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97\u2013105.","journal-title":"JAMA Oncol"},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021\u20133.","journal-title":"Blood"},{"key":"487_CR4","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S2352-3026(18)30108-X","volume":"5","author":"S Chattopadhyay","year":"2018","unstructured":"Chattopadhyay S, Zheng G, Sud A, Yu H, Sundquist K, Sundquist J, et al. Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. Lancet Haematol. 2018;5:e368\u2013e377.","journal-title":"Lancet Haematol"},{"key":"487_CR5","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","volume":"18","author":"MA Vannucchi","year":"2009","unstructured":"Vannucchi MA, Masala G, Antonioli E, Susini MC, Guglielmelli P, Pieri L, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome\u2014negative myeloproliferative neoplasms. Cancer Epidemiol Biomark Prev. 2009;18:2068\u201373.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"487_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.25049","volume":"93","author":"M Marchetti","year":"2018","unstructured":"Marchetti M, Carobbio A, Capitoni E, Barbui T. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review. Am J Hematol. 2018;93:698\u2013703.","journal-title":"Am J Hematol"},{"key":"487_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0038-3","volume":"8","author":"A Ghirardi","year":"2018","unstructured":"Ghirardi A, Carobbio A, Masciulli A, Barbui T. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer J. 2018;8:5.","journal-title":"Blood Cancer J"},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3324\/haematol.2010.033779","volume":"96","author":"E Rumi","year":"2011","unstructured":"Rumi E, Passamonti F, Elena C, Pietra D, Arcaini L, Astori C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96:454\u20138.","journal-title":"Haematologica"},{"key":"487_CR9","first-page":"2489","volume":"34","author":"J Kissova","year":"2014","unstructured":"Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I. Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res. 2014;34:2489\u201396.","journal-title":"Anticancer Res"},{"key":"487_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.leukres.2018.10.006","volume":"74","author":"G Birgeg\u00e5rd","year":"2018","unstructured":"Birgeg\u00e5rd G, Folkvaljon F, Garmo H, Holmberg L, Besses C, Griesshammer M, et al. Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leuk Res. 2018;74:105\u20139.","journal-title":"Leuk Res"},{"key":"487_CR11","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515\u201320.","journal-title":"Blood"},{"key":"487_CR12","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Bj\u00f6rkholm M, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32:2203\u201310.","journal-title":"Leukemia"},{"key":"487_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/10428194.2015.1041392","volume":"57","author":"L Masarova","year":"2016","unstructured":"Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, et al. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera\u2014single center experience. Leuk Lymphoma. 2016;57:237\u20139.","journal-title":"Leuk Lymphoma"},{"key":"487_CR14","first-page":"6","volume":"57","author":"L Marcheselli","year":"2016","unstructured":"Marcheselli L, Polliack A, Tadmor T. Impact of therapy on the development of second malignancies in essential thrombocythemia and polycythemia vera: are we comfortable about this? Leuk Lymphoma. 2016;57:6\u20137.","journal-title":"Leuk Lymphoma"},{"key":"487_CR15","first-page":"132","volume":"23","author":"PD Berk","year":"1986","unstructured":"Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132\u201343.","journal-title":"Semin Hematol"},{"key":"487_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.12410","volume":"94","author":"H Pettersson","year":"2015","unstructured":"Pettersson H, Knutsen H, Holmberg E, Andr\u00e9asson B. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152\u20136.","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"487_CR17","first-page":"S27","volume":"8","author":"G Gaidano","year":"1994","unstructured":"Gaidano G, Guerrasio A, Serra A, Rege-Cambrin G, Saglio G. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia. 1994;8(Suppl 1):S27\u2013S29.","journal-title":"Leukemia"},{"key":"487_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214\u201320.","journal-title":"Leuk Res"},{"key":"487_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ajh.23842","volume":"89","author":"R J\u00e4ger","year":"2014","unstructured":"J\u00e4ger R, Harutyunyan AS, Rumi E, Pietra D, Berg T, Olcaydu D, et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol. 2014;89:1107\u201310.","journal-title":"Am J Hematol"},{"key":"487_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/1055-9965.EPI-15-0805","volume":"25","author":"T Krahling","year":"2016","unstructured":"Krahling T, Balassa K, Kiss KP, Bors A, Batai A, Halm G, et al. Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100. Cancer Epidemiol Biomark Prev. 2016;25:98\u2013104.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"487_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1080\/10428194.2017.1312380","volume":"58","author":"L Le Clech","year":"2017","unstructured":"Le Clech L, Sakka M, Meskar A, Kerspern H, Eveillard JR, Berthou C, et al. The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. Leuk Lymphoma. 2017;58:2582\u20137.","journal-title":"Leuk Lymphoma"},{"key":"487_CR22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/archinte.165.15.1782","volume":"165","author":"RH White","year":"2005","unstructured":"White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165:1782\u20137.","journal-title":"Arch Intern Med"},{"key":"487_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/asheducation-2016.1.196","volume":"2016","author":"MB Streiff","year":"2016","unstructured":"Streiff MB. Thrombosis in the setting of cancer. Hematol Am Soc Hematol Educ Program. 2016;2016:196\u2013205.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"487_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3324\/haematol.2018.197814","volume":"103","author":"V De Stefano","year":"2018","unstructured":"De Stefano V. Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome. Haematologica. 2018;103:1419\u201321.","journal-title":"Haematologica"},{"key":"487_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","volume":"133","author":"BB Navi","year":"2019","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781\u20139.","journal-title":"Blood"},{"key":"487_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2003.11.059","volume":"51","author":"C Sanchez-Palacios","year":"2004","unstructured":"Sanchez-Palacios C, Guitart J. Hydroxyurea associated squamous dysplasia. J Am Acad Dermatol. 2004;51:293\u2013300.","journal-title":"J Am Acad Dermatol"},{"key":"487_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol. 2012;87:552\u20134.","journal-title":"Am J Hematol"},{"key":"487_CR28","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","volume":"89","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319\u201327.","journal-title":"Blood"},{"key":"487_CR29","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410\u20135.","journal-title":"J Clin Oncol"},{"key":"487_CR30","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907\u201313.","journal-title":"J Clin Oncol"},{"key":"487_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018;132:694\u2013706.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0487-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0487-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0487-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:37:39Z","timestamp":1684618659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0487-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0487-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"23 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TB has been a speaker and consultant for Novartis and he has received research grant from AOP Orphan. VDS has received consulting and lecture fees from Amgen, Celgene, Novartis, and institutional research grants from Bayer and Novartis. MLF has been a member of advisory Board for Novartis and she has received travel grants from the company. MFM has been a speaker and consultant for Novartis. MM has received honoraria for advisory boards and lectures at sponsored meetings from Celgene, Amgen, Janssen, Gilead, Novartis. AMV has been a speaker for Novartis, Celgene, and Shire and participated to advisory boards of Celgene, Incyte, Novartis. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}